Related Experiment Video
Updated: Jul 3, 2025
10:35
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
8.3K
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
Sander Rm Bus1, Rob J de Haan2, Marinus Vermeulen1
1Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
The Cochrane Database of Systematic Reviews
|February 14, 2024
Summary
Intravenous immunoglobulin (IVIg) significantly improves disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients within six weeks compared to placebo. IVIg shows similar short-term efficacy to prednisolone and IVMP, with benefits potentially lasting up to 24 weeks.
Area of Science:
- Neurology
- Immunology
Background:
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a neurological disorder causing progressive limb weakness and numbness.
- Intravenous immunoglobulin (IVIg) has been suggested as a potential treatment for CIDP symptoms.
Approach:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
- Assessed efficacy and safety of IVIg versus placebo, plasma exchange, or corticosteroids in CIDP patients.
- Primary outcome: significant disability improvement within six weeks; secondary outcomes included disability scores, muscle strength, and adverse events.
Key Points:
- IVIg significantly improves disability within six weeks compared to placebo (NNTB 4), with high-certainty evidence.
- IVIg shows comparable short-term efficacy to oral prednisolone and intravenous methylprednisolone (IVMP).
- Disability improvement with IVIg compared to placebo persisted for up to 24 weeks in one trial.
Conclusions:
- IVIg is an effective treatment for improving disability in CIDP patients in the short term.
- Further research is needed to evaluate the long-term benefits and harms of IVIg relative to other CIDP treatments.
